Tags

Type your tag names separated by a space and hit enter

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Neurology. 2012 Oct 16; 79(16):1636-44.Neur

Abstract

OBJECTIVES

Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living subjects. We prospectively evaluated the prognostic utility of detecting Aβ pathology using florbetapir PET in subjects at risk for progressive cognitive decline.

METHODS

A total of 151 subjects who previously participated in a multicenter florbetapir PET imaging study were recruited for longitudinal assessment. Subjects included 51 with recently diagnosed mild cognitive impairment (MCI), 69 cognitively normal controls (CN), and 31 with clinically diagnosed Alzheimer disease dementia (AD). PET images were visually scored as positive (Aβ+) or negative (Aβ-) for pathologic levels of β-amyloid aggregation, blind to diagnostic classification. Cerebral to cerebellar standardized uptake value ratios (SUVr) were determined from the baseline PET images. Subjects were followed for 18 months to evaluate changes in cognition and diagnostic status. Analysis of covariance and correlation analyses were conducted to evaluate the association between baseline PET amyloid status and subsequent cognitive decline.

RESULTS

In both MCI and CN, baseline Aβ+ scans were associated with greater clinical worsening on the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog (p < 0.01) and Clinical Dementia Rating-sum of boxes (CDR-SB) (p < 0.02). In MCI Aβ+ scans were also associated with greater decline in memory, Digit Symbol Substitution (DSS), and Mini-Mental State Examination (MMSE) (p < 0.05). In MCI, higher baseline SUVr similarly correlated with greater subsequent decline on the ADAS-Cog (p < 0.01), CDR-SB (p < 0.03), a memory measure, DSS, and MMSE (p < 0.05). Aβ+ MCI tended to convert to AD dementia at a higher rate than Aβ- subjects (p < 0.10).

CONCLUSIONS

Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline.

Authors+Show Affiliations

Duke University Medical Center, Durham, NC, USA. murali.doraiswamy@duke.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22786606

Citation

Doraiswamy, P Murali, et al. "Amyloid-β Assessed By Florbetapir F 18 PET and 18-month Cognitive Decline: a Multicenter Study." Neurology, vol. 79, no. 16, 2012, pp. 1636-44.
Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636-44.
Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., Grundman, M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., Clark, C. M., Joshi, A. D., Mintun, M. A., Skovronsky, D. M., & Pontecorvo, M. J. (2012). Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology, 79(16), 1636-44. https://doi.org/10.1212/WNL.0b013e3182661f74
Doraiswamy PM, et al. Amyloid-β Assessed By Florbetapir F 18 PET and 18-month Cognitive Decline: a Multicenter Study. Neurology. 2012 Oct 16;79(16):1636-44. PubMed PMID: 22786606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. AU - Doraiswamy,P Murali, AU - Sperling,Reisa A, AU - Coleman,R Edward, AU - Johnson,Keith A, AU - Reiman,Eric M, AU - Davis,Mat D, AU - Grundman,Michael, AU - Sabbagh,Marwan N, AU - Sadowsky,Carl H, AU - Fleisher,Adam S, AU - Carpenter,Alan, AU - Clark,Christopher M, AU - Joshi,Abhinay D, AU - Mintun,Mark A, AU - Skovronsky,Daniel M, AU - Pontecorvo,Michael J, AU - ,, Y1 - 2012/07/11/ PY - 2012/7/13/entrez PY - 2012/7/13/pubmed PY - 2012/12/27/medline SP - 1636 EP - 44 JF - Neurology JO - Neurology VL - 79 IS - 16 N2 - OBJECTIVES: Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living subjects. We prospectively evaluated the prognostic utility of detecting Aβ pathology using florbetapir PET in subjects at risk for progressive cognitive decline. METHODS: A total of 151 subjects who previously participated in a multicenter florbetapir PET imaging study were recruited for longitudinal assessment. Subjects included 51 with recently diagnosed mild cognitive impairment (MCI), 69 cognitively normal controls (CN), and 31 with clinically diagnosed Alzheimer disease dementia (AD). PET images were visually scored as positive (Aβ+) or negative (Aβ-) for pathologic levels of β-amyloid aggregation, blind to diagnostic classification. Cerebral to cerebellar standardized uptake value ratios (SUVr) were determined from the baseline PET images. Subjects were followed for 18 months to evaluate changes in cognition and diagnostic status. Analysis of covariance and correlation analyses were conducted to evaluate the association between baseline PET amyloid status and subsequent cognitive decline. RESULTS: In both MCI and CN, baseline Aβ+ scans were associated with greater clinical worsening on the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog (p < 0.01) and Clinical Dementia Rating-sum of boxes (CDR-SB) (p < 0.02). In MCI Aβ+ scans were also associated with greater decline in memory, Digit Symbol Substitution (DSS), and Mini-Mental State Examination (MMSE) (p < 0.05). In MCI, higher baseline SUVr similarly correlated with greater subsequent decline on the ADAS-Cog (p < 0.01), CDR-SB (p < 0.03), a memory measure, DSS, and MMSE (p < 0.05). Aβ+ MCI tended to convert to AD dementia at a higher rate than Aβ- subjects (p < 0.10). CONCLUSIONS: Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/22786606/Amyloid_β_assessed_by_florbetapir_F_18_PET_and_18_month_cognitive_decline:_a_multicenter_study_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&amp;pmid=22786606 DB - PRIME DP - Unbound Medicine ER -